Travere Therapeutics ROA 2024

Čo robí Travere Therapeutics?

Travere Therapeutics, Inc is a pharmaceutical company specializing in rare diseases. It was founded in 2019 and is headquartered in San Diego, California. Travere is tirelessly working to develop innovative therapies to improve the lives of patients with rare diseases. History Travere Therapeutics was formed from the merger of Retrophin, Inc and privately held company Censa Pharmaceuticals, Inc. Retrophin was founded in 2011 by Martin Shkreli and had difficulties in developing therapies for rare diseases. Shkreli later left the company and Retrophin focused on developing therapies for multiple rare diseases. In 2019, Retrophin merged with Censa Pharmaceuticals to form Travere Therapeutics, a company solely dedicated to rare diseases. Business Model Travere Therapeutics' business model is to develop innovative therapies for rare diseases that address an unmet medical need. With a strong focus on research and development, the company is working to discover, develop, and market new and life-changing therapies. Travere Therapeutics has a strong pipeline of drugs and medications in various stages of clinical development. This pipeline includes therapies for rare diseases such as nephrotic syndromes, mucopolysaccharidosis, lipid disorders, and others. Divisions Travere Therapeutics specializes in two business areas: pharmaceuticals and diagnostics. Pharmaceutical Business Travere Therapeutics' pharmaceutical business includes researching, developing, and marketing therapies for rare diseases. The company has a strong focus on research and development and has a pipeline of drugs and therapies aimed at improving the lives of patients with rare diseases. Diagnostics Business Travere Therapeutics' diagnostics business focuses on diagnostic tests for rare diseases. The company has partnerships with labs and facilities around the world specializing in diagnostics and genetics to ensure accurate diagnosis of patients with rare diseases. Products Travere Therapeutics offers a variety of products and therapies in different stages of development. Here are some of the key products the company offers: · Isturisa: a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of the hormone cortisol. · Re-PLAI: a medication for the treatment of nephrotic syndromes, a group of disorders caused by kidney dysfunction. · Enzyme Replacement Therapy (ERT): an approach to treating inherited metabolic disorders by administering missing enzymes. Conclusion Travere Therapeutics is an innovative company specializing in developing therapies for rare diseases. The company has a strong pipeline of drugs and the expertise to develop therapies for patients who are underserved by traditional medications. With a focus on research and diagnostics, the company has the potential to improve the lives of millions of patients with rare diseases. Travere Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.